ATRIVA (IDFF)
Financed · Germany
Source: European Investment Bank (EIB)
The project supports a biotech company to develop a novel antiviral medicinal product for influenza and other respiratory viruses, including, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The eligible investment plan includes R&D and related expenses.
- Status
- Prospective
- Sector
- Hospital, Hotel, Manufacturing (Industrial), Government
- Location
- Germany
- Updated
- 19 Nov 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about ATRIVA (IDFF)
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | financed |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | The project supports a biotech company to develop a novel antiviral medicinal product for influenza and other respiratory viruses, including, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The eligible investment plan includes R&D and related expenses. |
Original sector | Services |
Budget |
Location
Country | Germany |
Source
Source reliability | High |
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Sector | Hospital, Hotel, Manufacturing (Industrial), Government |
Article published date | 2023-05-08 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Germany
- Boehringer Ingelheim’s New Tablet Production Facility, Ingelheim
- Hameln Pharma Sterile Facility
- Takeda Pharmaceutical Manufacturing Facility, Oranienburg
- Merck Serono Biopharmaceutical R&D Facility Expansion, Darmstadt
- Evonik’s Pharmaceutical Lipids Manufacturing Facility, Hanau, Germany
- Wacker Chemie Biologics Production Facility
- Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany
- Haupt Pharma, New Packaging Line
